Innovega Inc.
Raising nowOperatingBiotech · Bellevue, WA · Founded 2008
Smart contact lenses and glasses that deliver high-performance AR/VR experiences
This company has an open fundraising round.
Financials
FY2019–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines, and each class is drawn as its own line.
Cap table
Share counts as of Jan 20, 2022These classes don't convert into each other and last sold at very different prices, so their share counts can't be added up into ownership percentages. Compare them by price instead.
| Class | Outstanding | Votes / share | Converts | Liquidation | Dividend | Last price |
|---|---|---|---|---|---|---|
| Series Seed Preferred Stockpreferred(as of Mar 30, 2021) | 3,518,238 | 1 | 1 × Common Stock | 1× · paid 1st | 8% | — |
| Series A-1 Preferred Stockpreferred | 1,868,345 | 1 | 1 × Common Stock | 1× · paid 1st | — | $5.50Aug 2026 |
| Series A-2 Preferred Stockpreferred | 1,610,514 | 1 | 1 × Common Stock | 1× · paid 1st | — | — |
| Series A-3 Preferred Stockpreferred | 1,123,787 | 1 | 1.022 × Common Stock | 1× · paid 1st | — | — |
| Common Stock | 9,447,968 | 1 | — | paid 2nd | — | — |
| Preferred Stockpreferred | 3,518,238 | 1 | — | — | — | $0.9762Oct 2023 |
Principal holders% as the filing states it, Aug 12, 2026
- Stephen Willey6,866,393 Common Stock24.4%of
Sold to the crowd
- Reg A+ · Mar 20211,919,205 shares at $3.00$5.8M· 2,839 investors
- Reg CF · Mar 2022193,573 shares at $3.00$580.7K· 520 investors
- Reg CF · Jul 2025633,103 shares at $3.00$1.9M· 942 investors
- Reg CF · Aug 2026154,329 shares at $5.50$848.8K· 233 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. “As converted” counts each class in the shares it converts into. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
9 people
Dr. Legerton enjoyed 26 years in private practice as a low vision and contact lens specialist before co-founding SynergEyes, the global leader in hybrid contact lenses. He brings a successful career in the commercialization of next-generation contact lenses and is an inventor on 59 issued U.S. patents and 79 published applications including those for multifocal, aberration blocking, hybrid, and scleral contact lenses; contact lenses for corneal refractive therapy, refractive error regulation, and wearable displays; and for diagnostic devices, refractive surgery, humanitarian eyewear and protective lighting. He is co-inventor of Paragon CRT® contact lens technology purchased by CooperVision. Contact lenses from his patents are registered in more than 45 countries. Dr. Legerton was honored for his contributions to the field of contact lens and corneal care with the American Optometric Association Outstanding Achievement Award; with the American Academy of Optometry, Founder’s Award; with the Orthokeratology Academy of America Achievement Award; and with the Contact Lens Manufacturers Association Trailblazer Award.
Steve holds graduate degrees in engineering, graphics, and business. Steve founded or co-founded multiple companies that achieved exits through acquisitions or IPO. At the start of his career, he joined Mobile Data International (MDI) and advanced to General Manager. MDI was a forerunner of modern-day cellular communications and was purchased by Motorola. In 1990, Steve joined CREO, a company later purchased by Kodak. He served as founding Director of eDispatch, listed on the TSE, Canada’s senior stock exchange. In 1995, Steve co-founded MicroVision, a leader in the development of novel pico-projector technologies for display eyewear and for mobile devices. Key customers included Sony, Canon, and other global OEMs. Steve was a member of the team that launched its NASDAQ IPO and later a NASDAQ IPO of spin-off, Lumera. Steve co-founded Innovega with a vision to change forever how human’s access, experience, and enjoy their media. Innovega is his driving passion.
Dr. Meyers began his career in the eyecare industry with Syntex Ophthalmics as Director, Researchand Development in 1983. He then served as Vice President, Research and Development, for Pilkington Barnes Hind for eight years and was responsible for multiple successfully commercialized contact lens products. After the successful sale of the company, he served as Vice President, Science and Technology for Paragon Vision Sciences, acquired by CooperVison. Six of his 39 issued US patents protect the global market leading product Paragon CRT®, the first FDA approved device for overnight reduction in myopia. Dr. Meyers received the award for Outstanding Achievement in the Field of Orthokeratology at the Vision by Design 2012 Conference.
Mr. Marsh has more than 25 years of product development experience for unprecedented systems in a multitude of industries including automotive, laser-based instrumentation, combustion physics research, contact lenses, and consumer electronics. Jay has a strong ability to function at all levels of the organization including parts manufacturing and assembly, chief engineer, and executive engineering leadership. While his formal education is mechanical engineering, he has gained deep exposure to a broad number of disciplines including electronics, optics, and software that provide strong leadership of the multidisciplinary teams that he builds for solving very hard problems. Jay is an inventor on 31 of Innovega’s 56 US and International patent cases.
Jeff Bradley is a Director of Innovega, and has served in this capacity since November 8, 2020. Mr. Bradley is currently a strategic advisor to other companies including Globys, Inc. as well as serving as a Board Director for the United Way of King County. Mr. Bradley retired from AT&T in June 2019 after 17 years of service. During the majority of his AT&T career, Mr. Bradley had responsibility for its smart device portfolio, network services marketing, and 3rd party developer program. This experience resulted in broad relationships across the technology ecosystem. Mr. Bradley ended his career with responsibility for AT&T’s west region retail sales and distribution which included over 1000 stores and 6000 employees. Mr. Bradley earned his BA in Economics from Stanford University in 1986.
Shane Kim is a Director of Innovega and has served in this capacity since 2017. As a strategic and operational leader in the interactive entertainment industry, Mr. Kim spent the majority of his 20-year career at Microsoft in its Xbox business, including leading Microsoft Game Studios, the publisher of leading industry franchises such as Halo and Age of Empires. From 2011 to 2019, Mr. Kim was a member of the board directors of GameStop, the world’s leading videogame and entertainment software retailer, and served as Interim Chief Executive Officer for 10 months during 2018 and 2019. Mr. Kim received Bachelor of Arts degrees in Economics and International Relations from Stanford University and a Master’s Degree in Business Administration from Harvard Business School.
Names and titles as disclosed on SEC Form 1-A, StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 1 of 1 annual reports (FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 52 filings on EDGAR- Form 1-SASep 28, 20260001493152-26-044547EDGAR
- Form CAug 12, 20260001474232-26-000013EDGAR
- Form C-ARAug 4, 20260001474232-26-000010EDGAR
- Form 1-KJul 8, 20260001493152-26-032545EDGAR
- Form C-UApr 1, 20260001474232-26-000005EDGAR
- Form C/AJan 30, 20260001474232-26-000004EDGAR
- Form C/AJan 29, 20260001474232-26-000002EDGAR
- Form C/AOct 23, 20250001474232-25-000005EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.